Bailard’s Tyra Biosciences TYRA Stock Holding History

Bailard’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,910	Closed	-$92K	–	765
2022 Q2	$92K	Buy	+12,910	New	+$103K	﹤0.01%	658

Other funds holding TYRA

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Bailard's TYRA Position: Q3 2022 in Review

Bailard sold out of Tyra Biosciences (TYRA) in Q3 2022, closing a stake of 12,910 shares — an estimated $92K sold.

Bailard first reported a position in TYRA in Q2 2022 and held it in 1 quarter. The position peaked at $92K in Q2 2022. 49 funds tracked by Wall St. Rank hold TYRA as of Q3 2022.

Bailard reported no remaining Tyra Biosciences position as of Q3 2022 after selling out during the quarter.
Bailard sold 12,910 Tyra Biosciences shares in Q3 2022, an estimated $92K.
Bailard first reported a position in Tyra Biosciences in Q2 2022 and held it in 1 quarter.
Bailard's Tyra Biosciences position peaked at $92K in Q2 2022.
49 funds tracked by Wall St. Rank held Tyra Biosciences as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.